BSR Biologics Registers patient information
The BSRBR-Rheumatoid Arthritis (BSRBR-RA) and Ankylosing Spondylitis (BSRBR-AS) registers are a unique collaboration between the British Society for Rheumatology, the Universities of Manchester and Aberdeen, and the pharmaceutical industry.
These registers were established to protect patients by detecting, at the earliest opportunity, any long-term or rare side-effects of TNFα inhibitors. The data patients provide - both directly through follow-up questionnaires and diaries, as well as via your rheumatology consultant - is important in helping researchers analyse the safety and effectiveness of biologic therapy compared to other treatments.
Further patient information on these drugs and disease is available on the excellent website of the National Rheumatoid Arthritis Society who provide support and information for people with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis, their families, friends and carers, and health professionals with an interest in Rheumatoid Arthritis.
Rheumatoid Arthritis Register
The RA register is the largest prospective register of rheumatology patients receiving anti-TNFα therapy in the world. To date, we have recruited over 20,000 participants to the register, all of whom are still under follow up via their consultant rheumatologist unless withdrawn or passed away. Over 40 journal articles have been published on the data that has been collected since the start of the study.
Ankylosing Spondylitis Register
The AS register is much newer, having opened in October 2012. The register recruits patients with ankylosing spondylitis who are being prescribed adalimumab or etanercept, as well as a control group of patients who have not been prescribed biologics, in order to detect any long term or rare side effects. It is hoped that in time, the AS register will achieve similar success to the RA register.